Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2010, Article ID 268547, 10 pages
http://dx.doi.org/10.1155/2010/268547
Research Article

High-Fat Diet-Induced Neuropathy of Prediabetes and Obesity: Effect of PMI-5011, an Ethanolic Extract of Artemisia dracunculus L.

1Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA
2Biotech Center, Cook College, Rutgers University, New Brunswick, NJ 08901-8554, USA
3Department of Nutritional Sciences, Cook College, Rutgers University, New Brunswick, NJ 08901-8554, USA

Received 1 December 2009; Revised 20 January 2010; Accepted 21 January 2010

Academic Editor: Giamila Fantuzzi

Copyright © 2010 Pierre Watcho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. M. Boulton, A. I. Vinik, and J. C. Arezzo, “Diabetic neuropathies: a statement by the American Diabetes Association,” Diabetes Care, vol. 28, no. 4, pp. 956–962, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. J. Sumner, S. Sheth, J. W. Griffin, D. R. Cornblath, and M. Polydefkis, “The spectrum of neuropathy in diabetes and impaired glucose tolerance,” Neurology, vol. 60, no. 1, pp. 108–111, 2003. View at Google Scholar · View at Scopus
  3. G. L. Pittenger, A. Mehrabyan, K. Simmons et al., “Small fiber neuropathy is associated with the metabolic syndrome,” Metabolic Syndrome and Related Disorders, vol. 3, no. 2, pp. 113–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Singleton and A. G. Smith, “Neuropathy associated with prediabetes: what is new in 2007?” Current Diabetes Reports, vol. 7, pp. 420–424, 2007. View at Google Scholar
  5. C. L. Oltman, L. J. Coppey, J. S. Gellett, E. P. Davidson, D. D. Lund, and M. A. Yorek, “Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats,” American Journal of Physiology, vol. 289, no. 1, pp. E113–E122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov et al., “High-fat diet-induced neuropathy of pre-diabetes and obesity: effects of “healthy“ diet and aldose reductase inhibition,” Diabetes, vol. 56, no. 10, pp. 2598–2608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Vincent, J. M. Hayes, L. L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E. L. Feldman, “Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1,” Diabetes, vol. 58, no. 10, pp. 2376–2385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Veves, M. Backonja, and R. A. Malik, “Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options,” Pain Medicine, vol. 9, no. 6, pp. 660–674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. I. G. Obrosova, “Diabetic Painful and Insensate Neuropathy: pathogenesis and Potential Treatments,” Neurotherapeutics, vol. 6, no. 4, pp. 638–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. X. Tan, W. F. Zheng, and H. Q. Tang, “Biologically active substances from the genus Artemisia,” Planta Medica, vol. 64, no. 4, pp. 295–302, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. L. E. Watson, P. L. Bates, T. M. Evans, M. M. Unwin, and J. R. Estes, “Molecular phylogeny of Subtribe Artemisiinae (Asteraceae), including Artemisia and its allied and segregate genera,” BMC Evolutionary Biology, vol. 26, pp. 2–17, 2002. View at Google Scholar
  12. N. S. D. Al-Waili, “Treatment of diabetes mellitus by Artemisia herba-alba extract: preliminary study,” Clinical and Experimental Pharmacology and Physiology, vol. 13, no. 7, pp. 569–573, 1986. View at Google Scholar · View at Scopus
  13. A. Subramoniam, P. Pushpangadan, S. Rajasekharan, D. A. Evans, P. G. Latha, and R. Valsaraj, “Effects of Artemisia pallens Wall. on blood glucose levels in normal and alloxan-induced diabetic rats,” Journal of Ethnopharmacology, vol. 50, no. 1, pp. 13–17, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Hong and I. S. Lee, “Effects of Artemisia capillaris ethyl acetate fraction on oxidative stress and antioxidant enzyme in high-fat diet induced obese mice,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 88–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Miño, V. Moscatelli, O. Hnatyszyn, S. Gorzalczany, C. Acevedo, and G. Ferraro, “Antinociceptive and antiinflammatory activities of Artemisia copa extracts,” Pharmacological Research, vol. 50, no. 1, pp. 59–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Ribnicky, A. Poulev, J. O'Neal et al., “Toxicological evaluation of the ethanolic extract of Artemisia dracunculus L. for use as a dietary supplement and in functional foods,” Food and Chemical Toxicology, vol. 42, no. 4, pp. 585–598, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. M. Ribnicky, A. Poulev, M. Watford, W. T. Cefalu, and I. Raskin, “Antihyperglycemic activity of Tarralin, an ethanolic extract of Artemisia dracunculus L.,” Phytomedicine, vol. 13, no. 8, pp. 550–557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Logendra, D. M. Ribnicky, H. Yang et al., “Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus,” Phytochemistry, vol. 67, no. 14, pp. 1539–1546, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. N. E. Cameron, M. A. Cotter, M. Basso, and T. C. Hohman, “Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats,” Diabetologia, vol. 40, no. 3, pp. 271–281, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Nakamura, K. Kato, Y. Hamada et al., “A protein kinase C-ß-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats,” Diabetes, vol. 48, no. 10, pp. 2090–2095, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Yagihashi, S.-I. Yamagishi, R.-I. Wada et al., “Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor,” Brain, vol. 124, no. 12, pp. 2448–2458, 2001. View at Google Scholar · View at Scopus
  22. I. G. Obrosova, C. Van Huysen, L. Fathallah, X. C. Cao, D. A. Greene, and M. J. Stevens, “An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense,” The FASEB Journal, vol. 16, no. 1, pp. 123–125, 2002. View at Google Scholar · View at Scopus
  23. E. C. M. Ho, K. S. L. Lam, S. C. Yuk et al., “Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage,” Diabetes, vol. 55, no. 7, pp. 1946–1953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. I. G. Obrosova, F. Li, O. I. Abatan et al., “Role of Poly(ADP-Ribose) polymerase activation in diabetic neuropathy,” Diabetes, vol. 53, no. 3, pp. 711–720, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Natarajan and J. L. Nadler, “Lipoxygenases and lipid signaling in vascular cells in diabetes,” Frontiers in Bioscience, vol. 8, supplement, pp. s783–s795, 2003. View at Google Scholar · View at Scopus
  26. R. Natarajan and J. L. Nadler, “Lipid inflammatory mediators in diabetic vascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 9, pp. 1542–1548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. P. A. Low, K. K. Nickander, and H. J. Tritschler, “The roles of oxidative stress and antioxidant. Treatment in experimental diabetic neuropathy,” Diabetes, vol. 46, supplement 2, pp. S38–S42, 1997. View at Google Scholar · View at Scopus
  28. N. E. Cameron, Z. Tuck, L. McCabe, and M. A. Cotter, “Effects of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes,” Diabetologia, vol. 44, no. 9, pp. 1161–1169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Shibata, K. Naruse, H. Kamiya et al., “Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats,” Diabetes, vol. 57, no. 11, pp. 3099–3107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. A. Greene, J. C. Arezzo, and M. B. Brown, “Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy,” Neurology, vol. 53, no. 3, pp. 580–591, 1999. View at Google Scholar · View at Scopus
  31. N. Hotta, T. Toyota, K. Matsuoka et al., “Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study,” Diabetes Care, vol. 24, no. 10, pp. 1776–1782, 2001. View at Google Scholar · View at Scopus
  32. A. S. Ametov, A. Barinov, P. J. Dyck et al., “The sensory symptoms of diabetic polyneuropathy are improved with a-lipoic acid: the Sydney trial,” Diabetes Care, vol. 26, no. 3, pp. 770–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. A. F. Sima, M. Calvani, M. Mehra, and A. Amato, “Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials,” Diabetes Care, vol. 28, no. 1, pp. 89–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. I. Vinik, V. Bril, P. Kempler et al., “Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C ß-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial,” Clinical Therapeutics, vol. 27, no. 8, pp. 1164–1180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Bril and R. A. Buchanan, “Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy,” Diabetes Care, vol. 29, no. 1, pp. 68–72, 2006. View at Google Scholar · View at Scopus
  36. N. E. Cameron, S. E. M. Eaton, M. A. Cotter, and S. Tesfaye, “Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy,” Diabetologia, vol. 44, no. 11, pp. 1973–1988, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. I. G. Obrosova, “Diabetes and the peripheral nerve,” Biochimica et Biophysica Acta, vol. 1792, no. 10, pp. 931–940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. P. J. Oates, “Aldose reductase, still a compelling target for diabetic neuropathy,” Current Drug Targets, vol. 9, no. 1, pp. 14–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. C. M. Casellini, P. M. Barlow, A. L. Rice et al., “A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-ß inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy,” Diabetes Care, vol. 30, no. 4, pp. 896–902, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. J. K. Grover, S. S. Rathi, and V. Vats, “Amelioration of experimental diabetic neuropathy and gastropathy in rats following oral administration of plant (Eugenia jambolana, Mucurna pruriens and Tinospora cordifolia) extracts,” Indian Journal of Experimental Biology, vol. 40, no. 3, pp. 273–276, 2002. View at Google Scholar · View at Scopus
  41. G. Zareba, “Phytotherapy for pain relief,” Drugs of Today, vol. 45, no. 6, pp. 445–467, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Ford, M. A. Cotter, N. E. Cameron, and M. Greaves, “The effects of treatment with α-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat,” Metabolism, vol. 50, no. 8, pp. 868–875, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. N. E. Cameron, A. M. Jack, and M. A. Cotter, “Effect of α-lipoic acid on vascular responses and nociception in diabetic rats,” Free Radical Biology and Medicine, vol. 31, no. 1, pp. 125–135, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. I. G. Obrosova, J. G. Mabley, Z. Zsengellér et al., “Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst,” FASEB Journal, vol. 19, no. 3, pp. 401–403, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. V. R. Drel, P. Pacher, I. Vareniuk et al., “Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes,” International Journal of Molecular Medicine, vol. 20, no. 6, pp. 783–792, 2007. View at Google Scholar · View at Scopus
  46. I. G. Obrosova, V. R. Drel, C. L. Oltman et al., “Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats,” American Journal of Physiology, vol. 293, no. 6, pp. E1645–E1655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Purves, A. Middlemas, S. Agthong et al., “A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy,” FASEB Journal, vol. 15, no. 13, pp. 2508–2514, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. S. A. Price, S. Agthong, A. B. Middlemas, and D. R. Tomlinson, “Mitogen-activated protein kinase p38 mediates reduced nerve conduction in experimental diabetic neuropathy: interactions with aldose reductase,” Diabetes, vol. 53, no. 7, pp. 1851–1856, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. D. LeRoith, V. Fonseca, and A. Vinik, “Metabolic memory in diabetes—focus on insulin,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 85–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Wang, A. M. Schmeichel, H. Iida, J. D. Schmelzer, and P. A. Low, “Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury,” Journal of the Neurological Sciences, vol. 247, no. 1, pp. 47–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. S.-I. Yamagishi, S. Ogasawara, H. Mizukami et al., “Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-?-ligand, in insulin-deficient diabetic rats,” Journal of Neurochemistry, vol. 104, no. 2, pp. 491–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. N. E. Cameron and M. A. Cotter, “Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway,” Current Drug Targets, vol. 9, no. 1, pp. 60–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Doupis, T. E. Lyons, S. Wu, C. Gnardellis, T. Dinh, and A. Veves, “Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 2157–2163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. C. S. Nunemaker, M. Chen, H. Pei et al., “12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet,” American Journal of Physiology, vol. 295, no. 5, pp. E1065–E1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. I. G. Obrosova, “Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications,” Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1543–1552, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. I. G. Obrosova, P. Pacher, C. Szabó et al., “Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications,” Diabetes, vol. 54, no. 1, pp. 234–242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. V. R. Drel, P. Pacher, M. J. Stevens, and I. G. Obrosova, “Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells,” Free Radical Biology and Medicine, vol. 40, no. 8, pp. 1454–1465, 2006. View at Publisher · View at Google Scholar · View at Scopus